The report presents the company's sustainability performance for the year 2022. Key highlights include the approval of the clinical trial for BYS10, a self-developed anti-cancer drug, by the US FDA; the company's commitment to integrity compliance and moral practice, with a focus on transparent business operations; the company's efforts to mitigate negative impacts on the environment and promote green development, including the launch of a large-scale plantation base for Banlangen in Xinjiang; and the company's support for rural revitalization through various projects and partnerships.
Issuing Company Baiyunshan Pharmaceutical Holdings Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 10.88 MB
No. of Pages 39 pages
Reporting periodJanuary 1, 2022-December 31, 2022
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI (GRI); Hong Kong Stock Exchange Environmental, Social and...
Materiality Assessmenttrue